2022 American Transplant Congress
Cd137 on Host Dendritic Cells Fine-Tunes the Intesity of Donor T Cells in Systemic Alloinmmune Responses
*Purpose: CD137 is a potent costimulatory receptor for CD8+ T cells but it also regulates dendritic cells (DCs) to suppress immune responses. In this study,…2022 American Transplant Congress
TIGIT Agonism Ameliorates Costimulation Blockade-Resistant Rejection by Increasing Quantity and Quality of Graft-Infiltrating Foxp3+ Treg
Emory University Transplant Center, Emory University, Atlanta, GA
*Purpose: Belatacept-based immunosuppression confers fewer off-target toxicities compared to CNI but comes at a cost of increased incidence and severity of acute rejection, potentially due…2022 American Transplant Congress
Selective CD28 Blockade Impacts T Cell Differentiation During Hematopoietic Reconstitution Following Lymphodepletion
*Purpose: Costimulation blockade targeting the CD28 pathway provides improved long-term transplant survival without the nephrotoxicity of calcineurin inhibitors. However, treatment with the CTLA-4Ig fusion protein…2022 American Transplant Congress
Real World Experience Utilizing Donor Kidneys at Risk for Acute Kidney Injury with Belatacept Based Maintenance Immunosuppression
University of Utah Health, Salt Lake City, UT
*Purpose: The demand for kidney transplant continues to rise, and limited supply has encouraged acceptance of marginal donor organs, such as those at risk for…2022 American Transplant Congress
Co-stimulation Patways Pd-1 (the Programmed Death 1) And Icos (the Inducible T Cell Co-stimulator) In Peripheral Mononuclear Cells Mesured By Flow Cytometry As A Possible Tool In The Follow-up And Diagnosis Of Kidney Transplant Rejection.
Posgrado de Ciencias médicas, Universidad Nacional Autonoma de México, CDMX, Mexico
*Purpose: Currently, the follow-up of KT in the clinic remains the creatinine levels, this is a highly specific, however, without sensitivity to determine diagnosis of…2022 American Transplant Congress
Clinically Available Immunosuppressive Agents Prolong Pig-to-Primate Kidney Xenograft Survival
1Surgery, Duke Transplant Center, Durham, NC, 2eGenesis Inc, Cambridge, MA
*Purpose: Most immunosuppressive regimens used in Pig-To-Primate Xenotransplantation contain anti-CD154 agents, compounds that are currently not FDA-approved. The aim of this study was to assess…2022 American Transplant Congress
Longitudinal Characterization of Memory B Cells During Antibody Mediated Rejection Treated with Plasmapheresis, Bortezomib, and Belatacept in Heart Transplant Recipients
*Purpose: Donor specific antibodies (DSA) and antibody mediated rejection (AMR) continue to limit allograft longevity after heart transplant. Effective treatments are limited and often complicated…2022 American Transplant Congress
Impact of Early Calcineurin-Inhibitor Conversion to Belatacept on Renal Allograft Function in a Steroid-Free Maintenance Regimen: Results from a Randomized Controlled Study
*Purpose: Belatacept (Bela) was developed to minimize nephrotoxicity and cardiovascular risk associated with Calcineurin inhibitors (CNIs). Early steroid withdrawal (ESW) and simultaneous CNI avoidance (CNIA)…2022 American Transplant Congress
Renal Function at Five Years from a Randomized Multicenter Trial of Belatacept-Based CNI Free and Early Steroid Withdrawal Immunosuppression
1University of Cincinnati, Cincinnati, OH, 2Christ Hospital, Cincinnati, OH
*Purpose: BENEFIT and BENEFIT EXT trials have demonstrated that belatacept-based immunosuppression was associated with improved long term renal allograft function compared to cyclosporine-based immunosuppression. Similar…2022 American Transplant Congress
Direct Comparison of Clinical Outcomes with Belatacept-Based Regimens to Calcineurin Inhibitors Among DCD and/or High KDPI Kidney Transplant Recipients
*Purpose: Belatacept, an inhibitor of the T-cell costimulatory pathway, can be used in recipients of Donation after Cardiac Death (DCD) and high Kidney Donor Profile…
- 1
- 2
- 3
- …
- 30
- Next Page »